John Engels - AxoGen Insider

AXGN -- USA Stock  

USD 51.35  0.40  0.77%

Co-Founder and VP

Mr. John P. Engels is Vice President of AxoGen, Inc., since September 30, 2011. He is a cofounder of AC and has served as ACs Vice President since June 2006, having provided operational and financial leadership and managing AxoGens strategic and product development partnerships until January 2012 when he assumed the leadership of international sales. From 1999 to 2002, Mr. Engels worked as a consultant for the University of Florida, Saffron Hill Ventures and PA Early Stage Partners, among other companies. From 1993 to 1997, Mr. Engels was an analyst and associate at CACM, a boutique investment banking firm. Mr. Engels is currently a member of the board of directors of Oxicool, Inc., a privatelyheld company developing new cooling technologies
Age: 44  Founder Since 2011  MBA    
Engels holds a MBA in Management and Operations from the Wharton School of Business at the University of Pennsylvania, and a BA from the University of Chicago.

John Engels Latest Insider Activity

John Engels over three months ago via Macroaxis 
AxoGen exotic insider transaction detected

Management Efficiency

The company has return on total asset (ROA) of (12.37) % which means that it has lost $12.37 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (72.88) % meaning that it created substantial loss on money invested by shareholders.
The company currently holds 24.59 M in liabilities with Debt to Equity (D/E) ratio of 113.3 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. AxoGen has Current Ratio of 3.25 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Entity Summary

AxoGen, Inc. develops and markets surgical solutions for peripheral nerve injuries. The company provides its products to hospitals, surgery centers, and military hospitals in the United States, Canada, the United Kingdom and other European countries, and internationally. AxoGen operates under Medical Devices classification in USA and traded on Nasdaq Capital Markets. It employs 184 people.AxoGen (AXGN) is traded on Nasdaq Capital Markets in USA. It is located in FLORIDA, U.S.A and employs 184 people. AxoGen is listed under Medical Equipment category by Fama And French industry classification.

AxoGen Leadership Team

Robert Rudelius, Director
Peter Mariani, CFO
Mark Friedman, President
John Engels, Founder, MBA
Jamie Grooms, Chairman
Shawn McCarrey, SVP
Amy Wendell, Director
Kevin Leach, President
Joseph Mandato, Director
Mike Donovan, Director, MBA
Erick DeVinney, President
Karen Zaderej, CEO, MBA
Kaila Krum, President
Gregory Freitag, President
David Hansen, Executive
Guido Neels, Director
Jon Gingrich, Executive
Mark Gold, Director
James Grooms, Chairman

Stock Performance Indicators

Current Sentiment - AXGN

AxoGen Investor Sentiment
Most of Macroaxis users are presently bullish on AxoGen. What is your sentiment towards investing in AxoGen? Are you bullish or bearish?
98% Bullish
2% Bearish

Pair Correlation

Equities Pair Trading Analysis
Correlation analysis and pair trading evaluation for AxoGen and Edwards Lifesciences. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Check also Trending Equities. Please also try Analyst Recommendations module to analyst recommendations and target price estimates broken down by several categories.